Summary
Hepatocellular carcinoma (HCC) accounts for >80% of patients with liver cancer and is one of the leading causes of cancer-associated mortalities, both worldwide and in the United States. Recent evidence highlights the involvement of YRDC (YrdC-threonylcarbamoyltransferase domain-containing protein), a tRNA modifying enzyme, in tumor growth via N6-threonylcarbamoylation (t6A) of tRNA in various cancer types, including HCC. Additionally, YRDC has been shown to be overexpressed in different types of cancer and associated with chemotherapeutic drug resistance as well as poor prognosis in HCC patie
